<s>
Fluciclovine	B-Application
(	O
18F	O
)	O
,	O
also	O
known	O
as	O
anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic	B-Application
acid	I-Application
(	O
anti-3	O
 [ 18F ] 	O
FACBC	O
)	O
,	O
or	O
as	O
Axumin	B-Application
(	O
brand	O
name	O
)	O
,	O
is	O
a	O
diagnostic	O
agent	O
indicated	O
for	O
positron	B-Application
emission	I-Application
tomography	I-Application
(	O
PET	O
)	O
imaging	O
in	O
men	O
with	O
suspected	O
prostate	O
cancer	O
recurrence	O
based	O
on	O
elevated	O
prostate	O
specific	O
antigen	O
(	O
PSA	O
)	O
levels	O
.	O
</s>
<s>
Axumin	B-Application
scans	O
were	O
compared	O
to	O
[11C]-tagged	O
choline	O
PET	B-Application
scans	I-Application
,	O
another	O
FDA	O
approved	O
PET	B-Application
scan	I-Application
that	O
can	O
assist	O
in	O
this	O
situation	O
,	O
and	O
to	O
biopsy	O
results	O
.	O
</s>
<s>
Fluciclovine	B-Application
tagged	O
PET	B-Application
scans	I-Application
appear	O
to	O
more	O
sensitive	O
than	O
CT	O
scans	O
and	O
to	O
[11C]-tagged	O
choline	O
PET	B-Application
scans	I-Application
.	O
</s>
<s>
Fluciclovine	B-Application
is	O
a	O
[18F]-tagged	O
synthetic	O
analog	O
of	O
the	O
amino	O
acid	O
L-leucine	O
.	O
</s>
<s>
The	O
distribution	O
of	O
the	O
tracer	O
in	O
the	O
body	O
differs	O
from	O
choline	O
and	O
FDG	B-Application
,	O
as	O
kidney	O
uptake	O
of	O
FACBC	O
is	O
negligible	O
,	O
and	O
no	O
activity	O
is	O
found	O
in	O
the	O
urinary	O
tract	O
.	O
</s>
<s>
There	O
is	O
low	O
native	O
brain	O
uptake	O
compared	O
to	O
FDG	B-Application
,	O
which	O
may	O
enhance	O
detection	O
of	O
brain	O
metastases	O
or	O
primary	O
brain	O
tumors	O
.	O
</s>
<s>
Axumin	B-Application
is	O
marketed	O
by	O
Blue	O
Earth	O
Diagnostics	O
,	O
Ltd.	O
,	O
United	O
Kingdom	O
.	O
</s>
